Shorter, gentler treatment tested for frail lymphoma patients

NCT ID NCT07215585

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing if a new treatment plan is better for older or frail adults with a type of blood cancer called large B-cell lymphoma. It compares a shorter course of standard chemotherapy followed by a new drug (AZD0486) against a longer course of standard chemotherapy alone. The goal is to see if the shorter plan works as well or better at controlling the cancer while being easier for patients to tolerate.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
NOT_YET_RECRUITING

Nedlands, 6009, Australia
Research Site
NOT_YET_RECRUITING

Antwerp, 2030, Belgium
Research Site
NOT_YET_RECRUITING

Brussels, 1200, Belgium
Research Site
RECRUITING

Ghent, 9000, Belgium
Research Site
RECRUITING

Leuven, 3000, Belgium
Research Site
NOT_YET_RECRUITING

Roeselare, 8800, Belgium
Research Site
NOT_YET_RECRUITING

Yvoir, 5530, Belgium
Research Site
RECRUITING

Porto Alegre, 90035-003, Brazil
Research Site
RECRUITING

São Paulo, 05652000, Brazil
Research Site
NOT_YET_RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Research Site
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
Research Site
NOT_YET_RECRUITING

Beijing, 100730, China
Research Site
NOT_YET_RECRUITING

Changchun, 130021, China
Research Site
NOT_YET_RECRUITING

Chengdu, 610041, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510060, China
Research Site
NOT_YET_RECRUITING

Jinan, 250117, China
Research Site
NOT_YET_RECRUITING

Nanchang, 330000, China
Research Site
RECRUITING

Shanghai, 200003, China
Research Site
NOT_YET_RECRUITING

Shanghai, 20032, China
Research Site
NOT_YET_RECRUITING

Hong Kong, 999077, Hong Kong
Research Site
NOT_YET_RECRUITING

Lai Chi Kok, Hong Kong
Research Site
WITHDRAWN

Shatin, 00000, Hong Kong
Research Site
RECRUITING

Bunkyō City, 113-8677, Japan
Research Site
RECRUITING

Kōtoku, 135-8550, Japan
Research Site
NOT_YET_RECRUITING

Matsumoto-shi, 399-8701, Japan
Research Site
NOT_YET_RECRUITING

Meguro-ku, 152-8902, Japan
Research Site
NOT_YET_RECRUITING

Osaka, 543-8555, Japan
Research Site
RECRUITING

Osaka, 545-8586, Japan
Research Site
NOT_YET_RECRUITING

Sunto-gun, 411-8777, Japan
Research Site
RECRUITING

Yamagata, 990-9585, Japan
Research Site
RECRUITING

Yokohama, 241-8515, Japan
Research Site
NOT_YET_RECRUITING

Kielce, 25-734, Poland
Research Site
RECRUITING

Krakow, 30-727, Poland
Research Site
NOT_YET_RECRUITING

Lodz, 93-513, Poland
Research Site
NOT_YET_RECRUITING

Lublin, 20-090, Poland
Research Site
NOT_YET_RECRUITING

Wroclaw, 50-367, Poland
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 5505, South Korea
Research Site
RECRUITING

Ankara, 06620, Turkey (Türkiye)
Research Site
RECRUITING

Antalya, 07025, Turkey (Türkiye)
Research Site
NOT_YET_RECRUITING

Glasgow, Scotland, G12 0YN, United Kingdom
Research Site
NOT_YET_RECRUITING

London, NW1 2PG, United Kingdom
Research Site
NOT_YET_RECRUITING

Newcastle upon Tyne, NE7 7AF, United Kingdom
Research Site
NOT_YET_RECRUITING

Nottingham, NG5 1PB, United Kingdom

Conditions

Explore the condition pages connected to this study.

LARGE B-CELL LYMPHOMA